Drug Profile
BDB 1
Alternative Names: BDB-001 - Beijing Defengrei Biotechnology; BDB-001 injection; BDB-1Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Beijing Defengrei Biotechnology
- Developer Beijing Defengrei Biotechnology; Staidson Beijing BioPharmaceuticals
- Class Anti-inflammatories; Antivirals; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Hidradenitis suppurativa
- Phase I/II Anti-neutrophil cytoplasmic antibody-associated vasculitis
Most Recent Events
- 22 Aug 2023 Staidson Beijing Biopharmaceuticals completes the phase II clinical trial in Hidradenitis suppurativa in China (IV) (NCT05093855)
- 06 Jun 2023 Beijing Defengrei Biotechnology completes a phase I/II trial in Hidradenitis suppurativa in China (NCT05103423)
- 21 Dec 2022 InflaRx amends co-development agreement with Staidson (Beijing) BioPharmaceuticals for the regulatory approval efforts for BDB 1 in China